Jefferies raised the firm’s price target on Insulet to $260 from $255 and keeps a Buy rating on the shares following the company’s “big beat” and guidance raise. Strength was broad-based geographically, says the analyst, who was “impressed by the quarter” and sees more product contributions ahead.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: